Patents Assigned to Tap Pharmaceuticals
-
Patent number: 12042491Abstract: Certain embodiments of the present disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain from 10 mg/ml to 100 mg/ml of a cinchona alkaloid or a quinolone compound, e.g. chloroquine or hydroxychloroquine, a solvent that is at least one of a glycerin, a propylene glycol (PG), and a polyethylene glycol (PEG); and a carbonate. In such formulations, the solvent and the carbonate are present in amounts sufficient to promote resistance to hydrogen peroxide mediated degradation of the cinchona alkaloid or quinoline.Type: GrantFiled: December 30, 2022Date of Patent: July 23, 2024Assignee: TaP Pharmaceuticals AGInventors: Nilesh Parikh, William Hite
-
Publication number: 20240238270Abstract: Certain embodiments of the present disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain from 10 mg/ml to 100 mg/ml of a cinchona alkaloid or a quinolone compound, e.g. chloroquine or hydroxychloroquine, a solvent that is at least one of a glycerin, a propylene glycol (PG), and a polyethylene glycol (PEG); and a carbonate. In such formulations, the solvent and the carbonate are present in amounts sufficient to promote resistance to hydrogen peroxide mediated degradation of the cinchona alkaloid or quinoline.Type: ApplicationFiled: December 30, 2022Publication date: July 18, 2024Applicant: TaP Pharmaceuticals, AGInventors: Nilesh PARIKH, William HITE
-
Publication number: 20240226086Abstract: Certain embodiments of the present disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain from 1 mg/ml to 300 mg/ml of chloroquine, hydroxychloroquine, or pharmaceutically acceptable salt(s) thereof and a solvent that is one or more of a glycerin, a propylene glycol, and a polyethylene glycol. Such formulations are free of added water and contain an amount of the the solvent is present sufficient to result in the chloroquine, hydroxychloroquine, or pharmaceutically acceptable salt thereof being in the solution phase of the formulation.Type: ApplicationFiled: December 29, 2022Publication date: July 11, 2024Applicant: TaP Pharmaceuticals, AGInventors: Nilesh PARIKH, William HITE
-
Patent number: 11980685Abstract: Certain embodiments of the present disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain an amount of a tafamidis of from 0.5 mg/ml to 20 mg/ml, water, and an amount of an alkaline pH modifier that yields a content of the tafamidis solubilized in the water of from 0.5 mg/ml to 19.8 mg/ml.Type: GrantFiled: December 23, 2022Date of Patent: May 14, 2024Assignee: TaP Pharmaceuticals, AGInventors: Nilesh Parikh, William Hite
-
Patent number: 11878081Abstract: Certain embodiments of the present disclosure provide pharmaceutical, unit-dose formulations, suitable for oral administration, that contain from 1% w/w to 20% w/w of a tafamidis-organic acid (such as adipic acid, glutaric acid, or fumaric acid) co-crystal; from 0.25% w/w to 2.5% w/w of an organic acid dissolution enhancer. Such formulations release, within 15 minutes in ¾ strength FeSSIF pH 5.8 or in FaSSIF+0.1% polysorbate 80 pH 6.5, at least 85% of the total tafamidis of the formulation.Type: GrantFiled: December 23, 2022Date of Patent: January 23, 2024Assignee: TaP Pharmaceuticals AGInventors: Nilesh Parikh, William Hite
-
Patent number: 11833138Abstract: Certain embodiments of the present disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain glycerol and an amount of apixaban in the solution phase of the formulations of from 0.5 mg/ml to 6 mg/ml.Type: GrantFiled: January 30, 2023Date of Patent: December 5, 2023Assignee: TaP Pharmaceuticals AGInventors: Nilesh Parikh, William Hite
-
Publication number: 20090042887Abstract: The present invention relates to methods of preventing gout flares in a subject in need thereof by administering to the subject a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof and at least one non-steroidal anti-inflammatory drug for a period of six months on a regular basis.Type: ApplicationFiled: January 17, 2008Publication date: February 12, 2009Applicant: TAP Pharmaceutical Products, Inc.Inventors: Christopher Lademacher, Patricia McDonald, Nancy Joseph Ridge, Rajneesh Taneja
-
Publication number: 20080292710Abstract: Liquid formulations of acid-labile drugs are provided. The formulations generally comprise micro-granules comprising an acid-labile drug coated with an enteric coating and a liquid vehicle having a pH less than 6.0. The components of the formulation can separately provided in the form of kits. The formulations and kits may be used to treat patients suffering from disorders for which the acid labile drugs are indicated.Type: ApplicationFiled: August 6, 2008Publication date: November 27, 2008Applicant: Tap Pharmaceutical Products, Inc.Inventor: Rajneesh Taneja
-
Publication number: 20080274200Abstract: Provided herein are pharmaceutical formulations comprising micro-granules and a liquid suspension vehicle having a pH less than 6.0 and a viscosity sufficient to suspend the micro-granules. The micro-granules typically contain a PPI which therefore makes the above formulation, as well as kits for making the above formulation, useful for alleviating the symptoms of gastrointestinal disorders or diseases.Type: ApplicationFiled: March 14, 2008Publication date: November 6, 2008Applicant: TAP PHARMACEUTICAL PRODUCTSInventor: Rajneesh TANEJA
-
Publication number: 20080200516Abstract: The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.Type: ApplicationFiled: December 28, 2007Publication date: August 21, 2008Applicant: TAP PHARMACEUTICAL PRODUCTS INC.Inventors: John M. BRACKETT, David T. JONAITIS, Wei LAI, Jih Hua LIU, Stephan D. PARENT, Jinyu SHEN
-
Publication number: 20080200517Abstract: The invention relates to crystalline forms of various solvates of ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising crystalline ilaprazole hydrate according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.Type: ApplicationFiled: December 28, 2007Publication date: August 21, 2008Applicant: TAP PHARMACEUTICAL PRODUCTS INC.Inventors: John M. BRACKETT, David T. JONAITIS, Wei LAI, Jih Hua LIU, Stephan D. PARENT
-
Publication number: 20080200515Abstract: The invention relates to solid state forms of enantiopure ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfnyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a solid form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders such as those discussed above.Type: ApplicationFiled: December 28, 2007Publication date: August 21, 2008Applicant: TAP PHARMACEUTICAL PRODUCTS INC.Inventors: John M. BRACKETT, David T. JONAITIS, Wei LAI, Jih Hua LIU, Stephan D. PARENT
-
Publication number: 20070244037Abstract: The invention discloses the human chemokine HCC-1, N-terminally truncated HCC-1 molecules and glycosylated HCC-1 which improve the homing of stem cells into the -bone marrow during stem cell transplantation. It is also provided a procedure for producing the polypeptides by recombinant techniques or chemical synthesis and for producing antibodies against such polypeptide. Furthermore, it is disclosed the modification of the polypeptide by coupling of amino acid residues and/or chemical groups or deleting amino-acids generating potent derivatives of the polypeptide. Another aspect of the invention provides a combination of the polypeptide of the present invention and a suitable pharmaceutical carrier for providing a therapeutically effective amount of the polypeptide for the treatment of various associated diseases.Type: ApplicationFiled: October 16, 2004Publication date: October 18, 2007Applicant: TAP PHARMACEUTICAL PRODUCTS INCInventors: Rudolf Richter, Reinhard Hen-Schler, Wolf-Georg Forssmann
-
Patent number: 6827208Abstract: The present invention relates to a packaging system intended to simplify the usage of multiple medications stored separately and used together, thereby minimize the non-compliant use of the multiple medications. Generally, the separate medication components are contained in a plurality of compartments, which when a deforming force is applied are released into an outer containment pouch. The medication components can then be mixed together and dispensed from the outer pouch.Type: GrantFiled: December 18, 2002Date of Patent: December 7, 2004Assignee: TAP Pharmaceutical Products Inc.Inventors: Pramod Gupta, Rajneesh Taneja
-
Patent number: 6528521Abstract: A method for treating sexual dysfunction that is caused by anti-depressant medication in a patient in need of such treatment, comprising administering a therapeutically effective amount of apomorphine, or a pharmaceutically acceptable salt thereof to said patient, is disclosed. The method may be utilized for patients taking anti-depressants such as tricyclic anti-depressants, monamine oxidase inhibitors or serotonin selective reuptake inhibitors.Type: GrantFiled: November 14, 2001Date of Patent: March 4, 2003Assignee: Tap Pharmaceutical Products, Inc.Inventors: Dustin D. Ruff, Renee J. Perdok
-
Patent number: 6506765Abstract: Apomorphine derivative compounds; pharmaceutically active compositions of apomorphine derivative compounds; and the use of apomorphine derivative compounds in methods for treating sexual dysfunction or for enhancing apomorphine effectiveness for patients treated with apomorphine are disclosed. The apomorphine derivatives may be esters, ethers, amides, mixed anhydrides, hemiacetals, glucuronates, sulfates or phosphonates. A preferred apomorphine derivative is norapomorphine.Type: GrantFiled: March 29, 2001Date of Patent: January 14, 2003Assignee: TAP Pharmaceutical Products, Inc.Inventors: Pramod K. Gupta, Deborah Milkowski, Debra Sutkowski-Markmann
-
Patent number: 5534548Abstract: Straight-chain alkanoic acids, substituted at the .OMEGA.-carbon atom by a substituted phenyl, naphthyl, furyl, or thienyl group and by a substituted 1,4-benzoquinon-2-yl group are effective in the therapy or prophylaxis of conditions associated with lipid peroxide injury to vascular endothelium particularly preeclampsia and eclampsia in pregnant females.Type: GrantFiled: May 3, 1994Date of Patent: July 9, 1996Assignee: TAP Pharmaceuticals, Inc.Inventor: Anthony Killian
-
Patent number: 5413990Abstract: Decapaptides substituted on the N-terminal nitrogen atom by acyl groups are potent antagonists of LHRH and are useful for suppressing the levels of sex hormones in mammals.Type: GrantFiled: August 6, 1993Date of Patent: May 9, 1995Assignee: Tap Pharmaceuticals Inc.Inventors: Fortuna Haviv, Timothy D. Fitzpatrick, Rolf E. Swenson, Charles J. Nichols, Nicholas A. Mort
-
Patent number: 5300492Abstract: The present invention relates to novel "pseudo" nonapeptide and decapeptide derivatives of LHRH. More particularly the present invention relates to derivatives of LHRH wherein the nitrogen atom of at least one of the amide bonds has been alkylated.Type: GrantFiled: October 28, 1991Date of Patent: April 5, 1994Assignee: Tap PharmaceuticalsInventors: Fortuna Haviv, Jonathan Greer
-
Patent number: 5140009Abstract: The present invention relates to novel LHRH analogs. The LHRH analogs include "pseudo" hexapeptide, heptapeptide, octapeptide and nonapeptide analogs of LHRH, wherein all or some of the amino acids, 1, 2 and 3 have been eliminated and the remaining (2-9), (2-10), (3-9), (3-10), (4-9) or (4-10) peptide is linked to various carboxylic acids which take the place of amino acids 1, 2 or 3 in LHRH.Type: GrantFiled: July 10, 1990Date of Patent: August 18, 1992Assignee: Tap Pharmaceuticals, Inc.Inventors: Fortuna Haviv, Jonathan Greer, Christopher A. Palabrica, Timothy D. Fitzpatrick